As previously reported, Oppenheimer downgraded Exelixis (EXEL) to Perform from Outperform with a price target of $33, down from $41. The firm is concerned about the differentiation of zanzalintinib versus cabozantinib following the abstract released ahead of the ASCO-GI meeting, the analyst tells investors. While the firm thinks the data from STELLAR-001 will likely derisk the Phase 3 STELLAR-303 study in metastatic colorectal cancer, it doesn’t “necessarily see clear differentiation” for zanzalintinib so it is moving to the sidelines for now.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Jefferies has two ‘contradictory’ conclusions after Exelixis abstract release
- Exelixis falls after ASCO releases colorectal cancer data
- Exelixis price target raised to $41 from $38 at Oppenheimer
- Exelixis price target raised to $42 from $38 at Truist
- Exelixis price target raised to $41 from $34 at JMP Securities